Bavituximab Anti-Cancer is a monoclonal antibody that targets a basic component of a cell’s membrane called phosphatidylserine (PS). Scientists working for Peregrine discovered that PS, which is normally found on the inside of healthy cell membranes, becomes exposed on the surface of tumor blood vessel cells. Bavituximab alerts the body’s immune system to attack the tumor blood vessel cells that exhibit exposed PS.

This has been shown to inhibit tumor growth and development. Bavituximab is not attracted to healthy cells in which PS is maintained on the interior of the membrane, thus the drug preferentially targets tumor blood vessels and potentially minimizes unwanted side effects. For more scientific information about bavituximab anti-cancer, click here.

Cancer Clinical Program. Bavituximab is currently in two separate Phase II combination therapy trials for the treatment of advanced breast cancer and a Phase II combination therapy trial for the treatment of non-small cell lung cancer. These trials are designed to assess the safety and efficacy of bavituximab when combined with standard chemotherapies docetaxel, paclitaxel and carboplatin. A Phase I bavituximab monotherapy trial in advanced solid cancers has been completed.